Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Zejula
Zejula is a cancer medicine used to help prevent recurrence of ovarian, fallopian tube, or primary peritoneal cancer after chemotherapy.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Niraparib
Niraparib is a substance used to treat certain cancers by blocking cancer cells' ability to repair DNA, helping prevent tumors from returning.
Niraparib Tosilate Monohydrate
Niraparib tosilate monohydrate is a substance that helps treat certain cancers by blocking cancer cells' ability to repair damaged DNA.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Graz
Gynaecology
Graz, Austria
Medical University of Vienna
Comprehensive Cancer Center, Medical University of Vienna
Vienna, Austria
L'Hopital Prive Du Confluent
Service d’oncologie médicale
Guilers, France

Sponsor: Glaxosmithkline Research & Development Limited
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.